Title: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are receiving the local standard of care.

Design: Adaptive, multiarm, controlled randomized clinical trial.

Primary Objective: to provide reliable estimates about any effects of the anti-viral treatments considered in the study on in-hospital mortality in moderate and in severe COVID-19.

Secondary Objective(s): 

• to assess any effects of anti-viral treatments on hospitalisation length, need for ventilation or for transfer to intensive care

• to identify any serious adverse reactions.

Originally, hydroxychloroquine, interferon (β1a), lopinavir/ritonavir and Remdesivir were selected as study drugs. After interim analysis, the protocol was amended and three study drugs originally selected (hydroxychloroquine, interferon (β1a), lopinavir/ritonavir) were stopped due to futility. 

The screening of several molecules is still ongoing to identify new possible study drugs.